Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, novembre 18
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Century Therapeutics Inc
IPSC
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$1.45
0.08
5.84%
Ult. Agg.: Nov 18, 12:09 PM
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 sono stati pubblicati in data gio nov 12th, prima dell'apertura del mercato
Century Therapeutics Financials
Century Therapeutics (IPSC) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Century Therapeutics Says Cash Runway Into Q1 2029; Cash & Investments $174.1M
Benzinga Newsdesk
PRO
Century Therapeutics Q3 EPS $(0.11) Vs $(0.40) YoY
Benzinga Newsdesk
PRO
Century Therapeutics Q2 EPS $(0.17) Misses $(0.14) Estimate
Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.14) by 21.43 percent. This is a 55.26 percent increase over losses of $(0.38) per
Benzinga Newsdesk
PRO
Century Therapeutics Q1 EPS $(0.11) Beats $(0.17) Estimate
Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 31.25 percent. This is a 112.36 percent decrease over earnings of $0.89 per share
Benzinga Newsdesk
PRO
Century Therapeutics Q4 EPS $(0.25) Beats $(0.27) Estimate
Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 8.42 percent. This is a 41.86 percent increase over losses of $(0.43) per share
Benzinga Newsdesk
PRO
Century Therapeutics Q3 EPS $(0.40) Misses $(0.34) Estimate
Century Therapeutics (NASDAQ:IPSC) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.34) by 18.34 percent. This is a 8.11 percent decrease over losses of $(0.37) per share
Benzinga Newsdesk